Is there a future for direct renin inhibitors?

Bibliography

• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;19(6):1105-87
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. hypertension 2003; 42(6):1206-52
   PubMed Web of Science ®Google Scholar
• Reudelhuber TL, Ramla D, Chiu L, Proteolytic processing of human prorenin in renal and non-renal tissues. Kidney Int 1994;46(6):1522-1524
   PubMed Web of Science ®Google Scholar
• Gaddam KK, Oparil S. Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients? Curr Opin Nephrol Hypertens 2008;17(5):484-90
   PubMed Web of Science ®Google Scholar
• Danser AH, Derkx FH, Schalekamp MA, Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998;16(6):853-62
   PubMed Web of Science ®Google Scholar
• Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003;326(1):15-24
   PubMed Web of Science ®Google Scholar
• Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005;23(1):S9-17
   PubMedGoogle Scholar
• Pimenta E, Oparil S. Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? Cardiol Clin 2008;26(4):527-35
   PubMed Web of Science ®Google Scholar
• Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-35
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9
   PubMed Web of Science ®Google Scholar
• Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148(1):30-48
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329(20):1456-62
   PubMed Web of Science ®Google Scholar
• Jorde UP. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact. Cardiol Rev 2006;14(2):81-7
   PubMedGoogle Scholar
• Azizi M, Menard J, Bissery A, Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15(12):3126-33
   PubMed Web of Science ®Google Scholar
• Belova LA. Angiotensin II-generating enzymes. Biochemistry (Mosc) 2000;65(12):1337-45
   PubMed Web of Science ®Google Scholar
• Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355(9204):637-45
   PubMed Web of Science ®Google Scholar
• Mooser V, Nussberger J, Juillerat L, Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990;15(2):276-82
   PubMed Web of Science ®Google Scholar
• Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev Cardiovasc Med 2006;7(2):45-54
   PubMed Web of Science ®Google Scholar
• Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957;106(3):439-53
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows SA, Patel S, Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370(9583):221-9
   PubMed Web of Science ®Google Scholar
• Pool JL, Schmieder RE, Azizi M, Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20(1):11-20
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358(23):2433-46
   PubMed Web of Science ®Google Scholar
• Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med 2008;358(23):2503-5
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Munger MA. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother 2007;41(3):456-64
   PubMed Web of Science ®Google Scholar
• Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7(5):399-410
   PubMed Web of Science ®Google Scholar
• Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008;51(5):519-28
   PubMed Web of Science ®Google Scholar
• Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39(1):E1-8
   PubMed Web of Science ®Google Scholar
• Zhao C, Vaidyanathan S, Yeh CM, Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006;45(11):1125-34
   PubMed Web of Science ®Google Scholar
• Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005;16(3):592-9
   PubMed Web of Science ®Google Scholar
• Danser AH, Charney A, Feldman DL, The renin rise with aliskiren: it's simply stoichiometry. Hypertension 2008;51(4):e27-28, e29
   PubMed Web of Science ®Google Scholar
• Sealey JE, Laragh JH. It is the plasma renin activity level that counts, not stoichiometry. Hypertension 2008;52(2):e20, e21
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. A brief response to Sealey and Laragh. J Renin Angiotensin Aldosterone Syst 2007;8(2):53
   PubMed Web of Science ®Google Scholar
• Wei Y, Sowers JR, Nistala R, Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 2006;281(46):35137-46
   PubMed Web of Science ®Google Scholar
• Whaley-Connell AT, Chowdhury NA, Hayden MR, Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006;291(6):F1308-14
   PubMed Web of Science ®Google Scholar
• Feldman DL, Jin L, Xuan H, Effects of aliskiren on blood pressure, albuminuria, and (pro) renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008;52(1):130-6
   PubMed Web of Science ®Google Scholar
• Danser AH. (Pro) renin receptors: are they biologically relevant? Curr Opin Nephrol Hypertens 2009;18(1):74-8
   PubMed Web of Science ®Google Scholar
• Ichihara A, Hayashi M, Kaneshiro Y, Inhibition of diabetic nephropathy by a decoy peptide corresponding to the ‘handle’ region for nonproteolytic activation of prorenin. J Clin Invest 2004;114(8):1128-35
   PubMed Web of Science ®Google Scholar
• Feldt S, Batenburg WW, Mazak I, Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008;51(3):682-8
   PubMed Web of Science ®Google Scholar
• Imanishi T, Tsujioka H, Ikejima H, Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008;52(3):563-72
   PubMed Web of Science ®Google Scholar
• Verma S, Gupta MK. Aliskiren improves nitric oxide bioavailability and limits atherosclerosis. Hypertension 2008;52(3):467-9
   PubMed Web of Science ®Google Scholar
• Carey RM. Antihypertensive and renoprotective mechanisms of Renin inhibition in diabetic rats. Hypertension 2008;52(1):63-4
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Malinin A, Barsness G, Effects of aliskiren, a renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease. J Hum Hypertens 2008;22(5):303-10
   PubMed Web of Science ®Google Scholar
• Lastra G, Habibi J, Whaley-Connell AT, Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009;150(6):2561-8
   PubMed Web of Science ®Google Scholar
• Whaley-Connell AT, Nistala R, Habibi J, Comparative Effect of Direct Renin Inhibition and AT1R Blockade on Glomerular Filtration Barrier Injury in the Transgenic Ren2 Rat. Am J Physiol Renal Physiol 2010;298(3):F655-61
   Google Scholar
• Habibi J, Whaley-Connell A, Hayden MR, Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 2008;149(11):5643-53
   PubMed Web of Science ®Google Scholar
• Bedair HS, Karthikeyan T, Quintero A, Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle. Am J Sports Med 2008;36(8):1548-54
   PubMed Web of Science ®Google Scholar
• Zaman AK, Fujii S, Goto D, Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol 2004;37(2):525-35
   PubMed Web of Science ®Google Scholar
• Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000;11(1):152-76
   PubMed Web of Science ®Google Scholar
• Pilz B, Shagdarsuren E, Wellner M, Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46(3):569-76
   PubMed Web of Science ®Google Scholar
• Nguyen G, Delarue F, Burckle C, Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109(11):1417-27
   PubMed Web of Science ®Google Scholar
• Schefe JH, Unger T, Funke-Kaiser H. PLZF and the (pro)renin receptor. J Mol Med 2008;86(6):623-7
   PubMed Web of Science ®Google Scholar
• Batenburg WW, de Bruin RJ, van Gool JM, Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008;28(6):1151-7
   PubMed Web of Science ®Google Scholar
• Jeunemaitre X, Menard J, Nussberger J, Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens 1989;2(11 Pt 1):819-27
   PubMed Web of Science ®Google Scholar
• Neutel JM, Luther RR, Boger RS, Weber MA. Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. Am Heart J 1991;122(4 Pt 1):1094-100
   PubMed Web of Science ®Google Scholar
• Uresin Y, Taylor AA, Kilo C, Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8(4):190-8
   PubMed Web of Science ®Google Scholar
• Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 2009;22(1):112-21
   PubMed Web of Science ®Google Scholar
• Nussberger J, Gradman AH, Schmieder RE, Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007;61(9):1461-8
   PubMed Web of Science ®Google Scholar
• Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42(6):1137-43
   PubMed Web of Science ®Google Scholar
• O'Brien E, Barton J, Nussberger J, Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007;49(2):276-84
   PubMed Web of Science ®Google Scholar
• Duprez DA, Davis P, Botha J. Abstract 4423: The AGELESS Study. The Effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients 65 Years of age with systolic hypertension. Circulation 2008;118:S886-7
   Web of Science ®Google Scholar
• Dechend R, Shagdarsuren E, Gratze P, Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. J Renin Angiotensin Aldosterone Syst 2007;8(2):81-4
   PubMed Web of Science ®Google Scholar
• Fisher ND, Jan Danser AH, Nussberger J, Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008;117(25):3199-205
   PubMed Web of Science ®Google Scholar
• Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32(3):387-92
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24(5):1663-71
   PubMed Web of Science ®Google Scholar
• Major TC, Olszewski B, Rosebury W, A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. Cardiovasc Drugs Ther 2008;22(6):469-78
   PubMed Web of Science ®Google Scholar
• Zhang Q, Kohara K, Qui HY, Hiwada K. Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Ther 1997;4(5-6):199-202
   PubMedGoogle Scholar
• Whaley-Connell A, Habibi J, Cooper SA, Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab 2008;295(1):E103-109
   PubMed Web of Science ®Google Scholar
• Fischer R, Dechend R, Qadri F, Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 2008;51(2):540-6
   PubMed Web of Science ®Google Scholar
• Neuberg GW, Kukin ML, Penn J, Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am J Cardiol 1991;67(1):63-6
   PubMed Web of Science ®Google Scholar
• Solomon SD, Appelbaum E, Manning WJ, Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119(4):530-537
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Pitt B, Latini R, Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1(1):17-24
   PubMed Web of Science ®Google Scholar
• Gratze P, Boschmann M, Dechend R, : Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity? Hypertension 2009;53(3):516-523
   PubMed Web of Science ®Google Scholar
• Stucchi P, Cano V, Ruiz-Gayo M, Fernandez-Alfonso MS. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol 2009;158(3):771-8
   PubMed Web of Science ®Google Scholar
• Dong YF, Liu L, Kataoka K, Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 2010;53(1):180-91
   Google Scholar
• Jordan J, Engeli S, Boye SW, Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49(5):1047-55
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Philipp T, Guerediaga J, Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009;27(7):1493-501
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. J Hypertens 2009;27(12):2321-31
   PubMed Web of Science ®Google Scholar
• Rashid H. Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren. Curr Med Res Opin 2008;24(9):2627-37
   PubMed Web of Science ®Google Scholar